Alosetron for irritable bowel syndrome

Editorial

Michel Lièvre. BMJ. 2002.

. 2002 Sep 14;325(7364):555-6.

doi: 10.1136/bmj.325.7364.555.

No abstract available

Comment in

Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
Palmer JB. Palmer JB. BMJ. 2003 Jan 4;326(7379):51. BMJ. 2003. PMID: 12511473 No abstract available.
Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
Palmer RH. Palmer RH. BMJ. 2003 Jan 4;326(7379):51. BMJ. 2003. PMID: 12518769 No abstract available.

FDA advisers warn of more deaths if drug is relaunched.
Moynihan R. Moynihan R. BMJ. 2002 Sep 14;325(7364):561. doi: 10.1136/bmj.325.7364.561. BMJ. 2002. PMID: 12228121 Free PMC article. No abstract available.
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
Moynihan R. Moynihan R. BMJ. 2002 Sep 14;325(7364):592-5. doi: 10.1136/bmj.325.7364.592. BMJ. 2002. PMID: 12228140 Free PMC article. Review. No abstract available.

1. Farthing MJG. Irritable bowel, irritable body, or irritable brain? BMJ. 1995;310:171–175. - PMC - PubMed
1. Office of Post-Marketing Drug Risk Assessment, FDA. Memorandum accessible through the Freedom of Information Act.
1. www.fda.gov/ohrms/dockets/ac/02/transcripts/3848T1.pdf (accessed 30 Aug 2002).
1. www.fda.gov/cder/drug (accessed 13 June 2002).
1. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Lancet. 2000;355:1035–1040. - PubMed